JP2012505665A - 脂肪組織から細胞集団を得る方法 - Google Patents

脂肪組織から細胞集団を得る方法 Download PDF

Info

Publication number
JP2012505665A
JP2012505665A JP2011532316A JP2011532316A JP2012505665A JP 2012505665 A JP2012505665 A JP 2012505665A JP 2011532316 A JP2011532316 A JP 2011532316A JP 2011532316 A JP2011532316 A JP 2011532316A JP 2012505665 A JP2012505665 A JP 2012505665A
Authority
JP
Japan
Prior art keywords
cells
population
cell
adipose tissue
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011532316A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012505665A5 (enExample
Inventor
アンソニー ドノフリオ，
ディレーラ モトラグ，
デイビッド エル． アムラニ，
エイミー コーエン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter Healthcare SA
Baxter International Inc
Original Assignee
Baxter Healthcare SA
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare SA, Baxter International Inc filed Critical Baxter Healthcare SA
Publication of JP2012505665A publication Critical patent/JP2012505665A/ja
Publication of JP2012505665A5 publication Critical patent/JP2012505665A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0653—Adipocytes; Adipose tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
JP2011532316A 2008-10-17 2009-10-19 脂肪組織から細胞集団を得る方法 Pending JP2012505665A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10635308P 2008-10-17 2008-10-17
US61/106,353 2008-10-17
PCT/US2009/061185 WO2010045645A1 (en) 2008-10-17 2009-10-19 Methods of obtaining cell populations from adipose tissue

Publications (2)

Publication Number Publication Date
JP2012505665A true JP2012505665A (ja) 2012-03-08
JP2012505665A5 JP2012505665A5 (enExample) 2012-12-06

Family

ID=41381576

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011532316A Pending JP2012505665A (ja) 2008-10-17 2009-10-19 脂肪組織から細胞集団を得る方法

Country Status (7)

Country Link
US (1) US20110274667A1 (enExample)
EP (1) EP2356214A1 (enExample)
JP (1) JP2012505665A (enExample)
CN (1) CN102186968A (enExample)
AU (1) AU2009305532A1 (enExample)
CA (1) CA2740578A1 (enExample)
WO (1) WO2010045645A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016017068A (ja) * 2014-07-10 2016-02-01 国立大学法人金沢大学 脂肪組織由来間質細胞群を含む消化管炎症治療剤
WO2017141831A1 (ja) * 2016-02-16 2017-08-24 ロート製薬株式会社 脂肪組織由来間質細胞を含む虚血性疾患治療剤およびその製造方法
JP2018533926A (ja) * 2015-10-08 2018-11-22 高雄醫學大學 脂肪間質細胞を急速分離する組成物

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9234897B2 (en) * 2005-03-31 2016-01-12 Two Cells Co., Ltd Method for distinguishing mesenchymal stem cell using molecular marker and use thereof
WO2013126590A2 (en) 2012-02-21 2013-08-29 Baxter International Inc. Pharmaceutical composition comprising cd34+ cells
WO2014089554A1 (en) * 2012-12-07 2014-06-12 Antria, Inc. Formulations containing and kit for using adipose-derived stem cells and use thereof
FR3024778B1 (fr) * 2014-08-05 2021-01-22 Screencell Procede pour le depistage de la drepanocytose et kit pour sa mise en oeuvre
US12161688B2 (en) 2016-06-30 2024-12-10 Mapi Pharma Ltd Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
CN106337036A (zh) * 2016-08-26 2017-01-18 杭州易文赛生物技术有限公司 一种提高脂肪组织中cd34阳性血管基质成分提取率的方法
CN106399234A (zh) * 2016-08-31 2017-02-15 肖锷 脂肪组织的处理方法及间充质干细胞、处理后单个脂肪细胞和细胞外基质
CA3062123A1 (en) 2017-05-15 2018-11-22 Stem Cell Medicine Ltd. Treatment of multiple sclerosis with adipose-derived stem cells
CN110709091A (zh) 2017-05-15 2020-01-17 干细胞医药有限公司 使用长效格拉替雷和脂肪源性干细胞治疗多发性硬化症
CN108261424B (zh) * 2018-01-24 2020-11-06 中国医学科学院医药生物技术研究所 一种肝癌的生物治疗方法
US20210369608A1 (en) * 2018-02-23 2021-12-02 Regeneration Biomedical, Inc. Methods, apparatuses and systems for instilling stem cells and pharmaceuticals into the human ventricular system
CN111518761B (zh) * 2020-05-25 2022-04-29 青岛瑞思德生物科技有限公司 一种间充质干细胞体外筛选、激活、扩增、冻存及其细胞库建立的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09508534A (ja) * 1994-06-14 1997-09-02 バクスター インターナショナル インコーポレイテッド ペプチド放出により媒介されるポジティブ細胞選択およびポジティブ／ネガティブ細胞選択
WO2007103379A2 (en) * 2006-03-07 2007-09-13 Humacyte Method for endothelial cell extraction from adipose tissues

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4808532A (en) * 1985-07-01 1989-02-28 The United States Of America As Represented By The United States Department Of Energy Continuous human cell lines and method of making same
EP1859025A4 (en) * 2005-01-31 2009-07-22 Cognate Therapeutics Inc PROPERTIES OF ENDOTHELIAL CELLS DISPLAYING ADAS (ADIPOSED DERIVED ADULT STROMAL) CELLS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09508534A (ja) * 1994-06-14 1997-09-02 バクスター インターナショナル インコーポレイテッド ペプチド放出により媒介されるポジティブ細胞選択およびポジティブ／ネガティブ細胞選択
WO2007103379A2 (en) * 2006-03-07 2007-09-13 Humacyte Method for endothelial cell extraction from adipose tissues

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN5012003217; ＦＲＡＳＥＲ，　Ｊ．Ｋ．，　ｅｔ　ａｌ．: 'ＤＩＦＦＥＲＥＮＣＥＳ　ＩＮ　ＳＴＥＭ　ＡＮＤ　ＰＲＯＧＥＮＩＴＯＲ　ＣＥＬＬ　ＹＩＥＬＤ　ＩＮ　ＤＩＦＦＥＲＥＮＴ　ＳＵＢＣＵＴＡＮＥＯＵＳ　ＡＤＩＰＯＳＥ　ＴＩＳＳＵＥ　ＤＥＰＯＴＳ' ＣＹＴＯＴＨＥＲＡＰＹ ９（５）, 2007, ｐｐ．４５９-４６７ *
JPN5012003219; ＦＲＡＳＥＲ，　Ｊ．Ｋ，　ｅｔ　ａｌ．: 'ＡＤＩＰＯＳＥ-ＤＥＲＩＶＥＤ　ＳＴＥＭ　ＣＥＬＬＳ' ＭＥＴＨＯＤＳ　ＩＮ　ＭＯＬＥＣＵＬＡＲ　ＢＩＯＬＯＧＹ ４４９, 200809, ｐｐ．５９-６７ *
JPN6014014858; ＹＯＳＨＩＭＵＲＡ，　Ｋ．，　ｅｔ　ａｌ．: ＪＯＵＲＮＡＬ　ＯＦ　ＣＥＬＬＵＬＡＲ　ＰＨＹＳＩＯＬＯＧＹ ２０８, 2006, ｐｐ．６４-７６ *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016017068A (ja) * 2014-07-10 2016-02-01 国立大学法人金沢大学 脂肪組織由来間質細胞群を含む消化管炎症治療剤
JP2018533926A (ja) * 2015-10-08 2018-11-22 高雄醫學大學 脂肪間質細胞を急速分離する組成物
WO2017141831A1 (ja) * 2016-02-16 2017-08-24 ロート製薬株式会社 脂肪組織由来間質細胞を含む虚血性疾患治療剤およびその製造方法
JPWO2017141831A1 (ja) * 2016-02-16 2018-12-06 ロート製薬株式会社 脂肪組織由来間質細胞を含む虚血性疾患治療剤およびその製造方法
JP7372736B2 (ja) 2016-02-16 2023-11-01 ロート製薬株式会社 脂肪組織由来間質細胞を含む虚血性疾患治療剤およびその製造方法

Also Published As

Publication number Publication date
EP2356214A1 (en) 2011-08-17
CN102186968A (zh) 2011-09-14
US20110274667A1 (en) 2011-11-10
WO2010045645A1 (en) 2010-04-22
CA2740578A1 (en) 2010-04-22
AU2009305532A1 (en) 2010-04-22

Similar Documents

Publication Publication Date Title
JP2012505665A (ja) 脂肪組織から細胞集団を得る方法
JP5767672B2 (ja) 組織修復のための混合細胞集団および細胞処理のための単離技術
JP5265190B2 (ja) 分化多能性増殖間葉系前駆細胞子孫（ｍｅｍｐ）およびその使用
JP6947430B2 (ja) 細胞培養方法
CN101248171B (zh) 通过组织非特异性碱性磷酸酶分离成人多潜能细胞
US20050249731A1 (en) Methods of implating mesenchymal stem cells for tissue repair and formation
JP5937210B2 (ja) 臍帯組織由来細胞を用いた末梢血管疾患の治療
JP2008526762A (ja) 組織再生および創傷治癒のための脂肪由来幹細胞
JP2010508818A5 (enExample)
WO2015004609A2 (en) Adherent cells from placenta and use thereof in treatment of injured tendons
JP2013506681A (ja) 腎損傷の処置における使用のための造血幹細胞
KR20180120261A (ko) 크론병의 난치성 복합 항문주위 누공 치료용 지방 조직 유래 기질 줄기 세포
US20100143476A1 (en) Composition for stimulating formation of vascular structures
US10293003B2 (en) Multilineage-differentiating stress enduring (MUSE) cells for treatment of chronic kidney disease
CN113853206A (zh) 脑梗塞的功能恢复
AU2015284180B2 (en) Gonad-derived side population stem cells
HK1161303A (en) Methods of obtaining cell populations from adipose tissue
US20170049823A1 (en) Pharmaceutical composition including three-dimensional cell cluster and angiopoietin for preventing and treating ischemic disease
WO2022123958A1 (en) Pharmaceutical composition for use in prevention and treatment of liver fibrosis and/or liver cirrhosis, comprising adipose-derived regenerative cells (adrcs)
HK40031113A (en) Eicosanoid production promoter
US20130287745A1 (en) Compositions and methods to stimulate vascular structure formation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121018

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140408

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141002